Evidence map›Paper›PMID 30569101›Full record

Trial reportMolecular medicine reports2019

Hypertonic saline maintains coagulofibrinolytic homeostasis following moderate‑to‑severe traumatic brain injury by regulating monocyte phenotype via expression of lncRNAs.

Xiping Yang, Yisheng Chen, Jianxin Li, Lijun Chen, Hefei Ren, Yang Liu, Xinyu Zhang

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xiping Yang *Department of Neurosurgery, The Affiliated Hospital of Logistic University of Chinese People's Armed Police Force, Tianjin 300162, P.R. China.
Yisheng Chen *Department of Neurosurgery, The Affiliated Hospital of Logistic University of Chinese People's Armed Police Force, Tianjin 300162, P.R. China.
Jianxin Li *Department of Neurosurgery, The Affiliated Hospital of Logistic University of Chinese People's Armed Police Force, Tianjin 300162, P.R. China.
Lijun ChenDepartment of Biochemistry and Physiology, Logistic University of Chinese People's Armed Police Force, Tianjin 300309, P.R. China.
Hefei RenGraduate Management Team, Logistic University of Chinese People's Armed Police Force, Tianjin 300309, P.R. China.
Yang LiuDepartment of Neurology, Shanghai Fourth People's Hospital, Shanghai 200000, P.R. China.
Xinyu ZhangDepartment of Biochemistry and Physiology, Logistic University of Chinese People's Armed Police Force, Tianjin 300309, P.R. China.
Logistics University of People's Armed Police Force · CNChinese People's Armed Police ForceTaizhou Fourth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traumatic brain injury (TBI) is the most common cause of death and permanent disability in people aged <45, and is associated with secondary brain injury and bleed progression, resulting in increased morbidity and mortality. TBI may also induce innate host defense responses characterized by activation of resident microglia and astrocytes, brain microvascular endothelial cells and peripheral blood monocytes. In the present study, 34 patients with moderate‑to‑severe traumatic brain injury were randomly divided into two groups, including a 7.5% hypertonic saline (HS) treatment group (4 ml/kg) and 3% HS treatment group (4 ml/kg). The results demonstrated that treatment with 7.5% HS decreased the intracranial pressure and improved coagulofibrinolytic homeostasis. Analysis of the monocyte subsets revealed significant reduction in the proportion of cluster of differentiation (CD)14++CD16+ circulating inflammatory monocytes in the 7.5% HS group. In addition, 7.5% HS treatment downregulated the expression of long non‑coding (lnc) RNA2448‑11 and lncRNA1403 in the peripheral blood mononuclear cells of patients with TBI. Using reverse transcription‑quantitative polymerase chain reaction, it was determined that 7.5% HS regulated the expression of tumor necrosis factor‑α, interleukin‑1β, transforming growth factor‑β and thrombomodulin, which are the target genes of lncRNA2448‑11 and lncRNA1403. These results indicated that 7.5% HS improved the intracranial pressure and coagulofibrinolytic homeostasis by modulating the phenotype of monocytes through lncRNA2448‑11 and lncRNA1403. These findings provided evidence that initial resuscitation with HS imparts functional changes to inflammatory cells following TBI, thereby reducing potential neuroinflammatory events associated with secondary brain injury.

Indexed as

AdolescentAdultAntifibrinolytic AgentsBlood CoagulationBrainBrain Injuries, TraumaticFemaleGene Expression RegulationGlasgow Coma ScaleHomeostasisHumansInterleukin-1betaIntracranial PressureMaleMiddle AgedMonocytesAntifibrinolytic AgentsIL1B protein, humanInterleukin-1betaNeuroprotective AgentsRNA, Long NoncodingSaline Solution, HypertonicTGFB1 protein, humanTHBD protein, humanThrombomodulinTransforming Growth Factor beta1Tumor Necrosis Factor-alphacoagulofibrinolytic homeostasishypertonic salinelncRNAsmonocyte phenotypetraumatic brain injury

Identifiers

PMID30569101
PMCPMC6323211
OpenAlexW2904770024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.